ArticleLeukemia2026

The adverse prognostic impact of HMGCLL1 gene variants can be abrogated by frontline second-generation tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.

Maria Agustina Perusini et al.PubMed ↗Publisher ↗

No numbers read from the abstract.